Platform
Second Genome's proprietary Microbiome Discovery Platform uniquely addresses current limitations in target discovery and validation by integrating computational science, machine learning with human disease biology to redefine diseases, and generate libraries of compounds that are screened in traditional drug discovery and development assays.
Pipeline
Our lead program, SG-2-0776, is a novel therapeutic protein derived from the microbiome that promotes mucosal healing of damaged epithelial surfaces. SG-2-0776 is currently in pre-clinical and IND-enabling studies, and we plan to initiate clinical studies in 2020.
News
April 10, 2019
FORTUNE and Great Place to Work Name Second Genome a "Top 10 Best Workplace in Biopharma"
March 26, 2019
January 23, 2019
September 26, 2018
Second Genome Appoints Karim Dabbagh, Ph.D., as Chief Executive Officer
